Remove Business Development Remove Gene Therapy Remove Genomics
article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Ultragenyx uses adeno-associated virus 8 (AAV8) gene therapy to induce stable OTC gene expression. This treatment activates the OTC gene so that ammonia can be removed from the blood. This gene therapy will give the instructions to produce the enzyme arginine so that it can be hydrolysed to ornithine.

RNA 245
article thumbnail

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan

The Pharma Data

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

The Pharma Data

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.

article thumbnail

BioSpace Movers & Shakers, Nov. 6

The Pharma Data

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Before joining Kite, he was chief scientific officer at Dutch AM-Pharma, Business Unit Manager at TNO Biosciences and chief executive officer at SomantiX.

Genome 40
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105
article thumbnail

The new frontiers of pharmaceutical innovation – according to investors ?

Pharmaceutical Technology

Research – and money – going into even more advanced gene therapies is ramping up. One significant growth area is the rise of genomics. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Figure 2: Mega-investments in the pharmaceutical industry since 2018.

article thumbnail

Bayer Continues Eying Potential Partnerships in Cell and Gene Therapy Space

The Pharma Data

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Also in December, the company partnered with Atara Biotherapeutics to develop off-the-shelf T-cell immunotherapies for high mesothelin-expressing tumors. Photo courtesy of Bayer.